Lack Of Competition Equals Higher Drug Prices: HHS Analysis Is Slogan In Search Of Solutions

Findings could provide a basis for future policy interventions, the department says. Speeding generics and biosimilars would seem a natural outshoot of the conclusions, but the report does not contain any recommendations.

Report Spotlights Lack Of Competition In Biologics Sector • Source: Shutterstock

The US Health and Human Services Department’s new analysis of the level of competition in various segments of the pharmaceutical industry fits the Biden Administration’s focus on promoting competition as a way of lowering prices. But it’s not clear what policies the paper would support.

The analysis was conducted by the HHS Assistant Secretary for Planning and Evaluation. It was released by the Biden...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access